iRhythm Technologies, Inc. (IRTC) stock declined over -1.27%, trading at $116.28 on NASDAQ, down from the previous close of $117.78. The stock opened at $119.48, fluctuating between $115.11 and $119.48 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 20, 2026 | 118.12 | 118.12 | 115.11 | 116.28 | 570.85K |
| Mar 19, 2026 | 117.55 | 119.94 | 115.65 | 117.78 | 331.77K |
| Mar 18, 2026 | 116.01 | 117.98 | 114.27 | 117.33 | 567.61K |
| Mar 17, 2026 | 113.95 | 117.78 | 113.85 | 117.53 | 893.31K |
| Mar 16, 2026 | 114.30 | 116.42 | 112.85 | 113.77 | 674.96K |
| Mar 13, 2026 | 115.00 | 116.53 | 112.31 | 113.00 | 630.7K |
| Mar 12, 2026 | 118.08 | 120.70 | 113.81 | 114.67 | 642.82K |
| Mar 11, 2026 | 120.73 | 122.63 | 119.50 | 119.64 | 504.37K |
| Mar 10, 2026 | 123.57 | 123.80 | 120.14 | 120.53 | 380.82K |
| Mar 09, 2026 | 121.62 | 124.23 | 119.75 | 123.75 | 476.82K |
| Mar 06, 2026 | 126.77 | 128.89 | 122.20 | 123.59 | 637.58K |
| Mar 03, 2026 | 127.30 | 128.53 | 119.78 | 125.85 | 584.62K |
| Mar 02, 2026 | 129.05 | 131.29 | 123.75 | 128.46 | 1.26M |
| Feb 27, 2026 | 137.74 | 141.46 | 132.07 | 133.75 | 703.23K |
| Feb 26, 2026 | 137.25 | 140.67 | 136.01 | 140.18 | 384.81K |
| Feb 25, 2026 | 136.64 | 138.29 | 133.46 | 135.90 | 497.56K |
| Feb 24, 2026 | 140.91 | 141.72 | 135.53 | 137.10 | 669.35K |
| Feb 23, 2026 | 148.13 | 148.18 | 138.03 | 141.22 | 943.52K |
| Feb 20, 2026 | 155.36 | 164.69 | 142.99 | 150.96 | 1.95M |
| Feb 19, 2026 | 154.03 | 159.64 | 151.46 | 158.88 | 775.23K |
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
| Employees | 2000 |
| Beta | 1.15 |
| Sales or Revenue | $492.68M |
| 5Y Sales Change% | 1.617% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep